Healthcare - Biotechnology - NASDAQ - US
$ 8.83
10.1 %
$ 408 M
Market Cap
-3.94
P/E
BALANCE SHEET
340 M
ASSETS
32.1 M
LIABILITIES
308 M
EQUITY
BALANCE SHEET DECOMPOSITION
Balance Sheet Decomposition
4D Molecular Therapeutics, Inc.
| Current Assets | 297 M |
| Cash & Short-Term Investments | 288 M |
| Receivables | 0 |
| Other Current Assets | 8.36 M |
| Non-Current Assets | 43.3 M |
| Long-Term Investments | 11 M |
| PP&E | 31.7 M |
| Other Non-Current Assets | 684 K |
| Current Liabilities | 19 M |
| Accounts Payable | 3.52 M |
| Short-Term Debt | 6.3 M |
| Other Current Liabilities | 9.14 M |
| Non-Current Liabilities | 13.1 M |
| Long-Term Debt | 11.5 M |
| Other Non-Current Liabilities | 1.59 M |
Balance Sheet
Millions
| Dec-2023 | Dec-2022 | Dec-2021 | Dec-2020 | Dec-2019 | Dec-2018 | Dec-2017 | |
|---|---|---|---|---|---|---|---|
| ASSETS | |||||||
| Cash & Cash Equivalents | 249.1 | 218.6 | 315.4 | 276.7 | 49.7 | 91.8 | 23.9 |
| Short Term Investments | 39.1 | 161.2 | 94.8 | 0 | 0 | 0 | 0 |
| Receivables | 0 | 0 | 47 K | 1.5 | 1.0 | 1.1 | 0.3 |
| Inventory | 0 | (5.8) | (8.5) | 0 | 0 | 0 | 1 |
| Other Current Assets | 8.4 | 7.0 | 8.5 | 8.9 | 1.9 | 0.8 | 0.3 |
| Total Current Assets | 296.6 | 220.5 | 315.4 | 282.7 | 52.5 | 94.1 | 24.5 |
| PP&E | 31.7 | 35.3 | 29.0 | 5.1 | 5.0 | 2.5 | 2.7 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Long Term Investments | 11.0 | 4.9 | 67.7 | 0 | 0 | 0 | 0 |
| Other Long Term Assets | 0.7 | 1.1 | (58.5) | 0.6 | 0.7 | 0.4 | 0.1 |
| Other Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Assets | 339.9 | 261.8 | 353.5 | 288.3 | 58.2 | 97.0 | 27.3 |
| LIABILITIES | |||||||
| Accounts Payable | 3.5 | 3.3 | 4.8 | 1.8 | 1.7 | 1.0 | 0.5 |
| Short Term Debt | 6.3 | 5.3 | 2.5 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 9.6 | 6.7 | 9.0 | 8.4 | 5.3 | 2.1 | 1.0 |
| Total Current Liabilities | 19.0 | 15.7 | 16.3 | 16.7 | 13.0 | 8.1 | 5.9 |
| Long Term Debt | 11.5 | 13.5 | 15.2 | 0 | 0 | 0 | 0 |
| Deferred Tax Income | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Liabilities | 0.6 | 0.2 | 0.3 | 2.0 | 104.6 | 103.4 | 18.8 |
| Total Liabilities | 32.1 | 30.5 | 560.5 | 31.9 | 131.2 | 124.6 | 46.9 |
| EQUITY | |||||||
| Common Stock | 4 K | 3 K | 3 K | 3 K | 1 K | 1 K | 1 K |
| Retained Earnings | (415.3) | (314.5) | (207.0) | (135.7) | (79.0) | (30.0) | (20.5) |
| Other Accumulative Comprehensive Income/Loss | 16 K | (1.2) | (0.4) | (288.3) | (103.0) | (103.0) | (18.5) |
| Total Equity | 307.8 | (314.5) | (207.0) | 256.4 | (73.0) | (27.6) | (19.6) |
| Total Liabilities and Equity | 339.9 | (284.0) | 353.5 | 288.3 | 58.2 | 97.0 | 27.3 |
| SHARES OUTSTANDING | |||||||
| Common Shares Outstanding | 39.1 | 32.4 | 27.7 | 26.7 | 26.5 | 12.5 | 14.8 |